| abstract |
The invention relates to the use of oxidation products of various phospholipid categories (phosphatidylcholines, ethanolamines, phosphatidylserines) for inhibiting the activation of TLR4 by LPS and the inflammatory processes resulting therefrom, in vitro and in vivo, by inhibiting LPS-induced signal transduction paths, the expression of inflammatory genes, tissue damage or the like. The invention also relates to the use of OXPAPC for treating the formation of oedemae and entotoxin-induced shock. |